NTRA
Natera, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +10.5% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 6 | 0 | 535.21K | $217.82M | n/a | n/a |
| Q2 2026 | 162 | 0 | 104.13M | $28.25B | +5 | −4 |
| Q1 2026 | 164 | +3 | 98.65M | $19.54B | +6 | −4 |
| Q4 2025 | 160 | 0 | 102.31M | $23.44B | +1 | n/a |
| Q3 2025 | 23 | +1 | 81.70M | $13.15B | +1 | −1 |
| Q2 2025 | 20 | -1 | 57.32M | $9.68B | n/a | −1 |
| Q1 2025 | 18 | 0 | 31.15M | $4.40B | n/a | n/a |
| Q4 2024 | 18 | 0 | 26.97M | $4.27B | n/a | n/a |
| Q3 2024 | 17 | -1 | 21.42M | $2.72B | n/a | −1 |
| Q2 2024 | 18 | n/a | 16.29M | $1.76B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 6.74M | +134.9% | $1.07B | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 2 | Duquesne Family Office ✦ | 3.57M | 0.0% | $564.63M | 15.9% | Held | 3 | SEC ↗ |
| 3 | Wellington Management ✦ | 3.24M | +15.7% | $512.90M | 0.1% | ▲ Add | 3 | SEC ↗ ×4 |
| 4 | State Street Global Advisors ✦ (passive) | 2.99M | n/a | $473.47M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 2.23M | +6.8% | $355.81M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 6 | Citadel Advisors ✦ | 1.43M | -37.1% | $226.52M | 0.2% | ▼ Trim | 3 | SEC ↗ ×2 |
| 7 | Norges Bank ✦ (passive) | 1.42M | +3.0% | $224.04M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 945.51K | +21.8% | $149.67M | 0.2% | ▲ Add | 3 | SEC ↗ ×4 |
| 9 | ARK Investment Management ✦ | 887.71K | +29.1% | $140.52M | 1.2% | ▲ Add | 3 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 806.33K | -22.2% | $127.64M | 0.1% | ▼ Trim | 3 | SEC ↗ ×2 |
| 11 | Marshall Wace ✦ | 434.44K | -3.7% | $68.77M | 0.1% | ▼ Trim | 3 | SEC ↗ ×2 |
| 12 | Millennium Management ✦ | 396.84K | -72.0% | $62.82M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 13 | Capital World Investors ✦ | 396.42K | 0.0% | $62.75M | 0.0% | Held | 3 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 394.00K | -13.6% | $62.37M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 374.37K | -3.7% | $59.26M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 16 | Point72 Asset Management ✦ | 305.24K | -56.2% | $48.32M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 17 | Arrowstreet Capital ✦ | 296.37K | +874.1% | $46.92M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 109.50K | +9.9% | $17.33M | 0.2% | ▲ Add | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 755 holders, 120.14M shares, $20.15B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 627 sh · $257,003
Director · 605 sh · $248,847
Director · 962 sh · $392,745
Director · 125 sh · $51,631
Director · 211 sh · $86,974
Director · 255 sh · $105,995
Director · 165 sh · $68,751
Director · 200 sh · $81,300
Director · 80 sh · $32,484
Director · 50 sh · $20,258
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology